ANTI-CD38 MONOCLONAL ANTIBODIES: TRANSFORMING MULTIPLE MYELOMA TREATMENT

ANTI-CD38 MONOCLONAL ANTIBODIES: TRANSFORMING MULTIPLE MYELOMA TREATMENT

Introduction: Multiple myeloma (MM) is a neoplasm defined by the clonal proliferation of malignant plasma cells (PC) within the bone marrow (BM). Multiple myeloma (MM) originates from the asymptomatic proliferation of pre-malignant plasma cells, categorized as monoclonal gammopathy of undetermined s...

Full description

Saved in:

Bibliographic Details
Main Author:	Cem Selim
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137924029511
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
by: Alberto L. Horenstein, et al.
Published: (2025-02-01)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01)

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
by: Muhammad Osama, et al.
Published: (2025-01-01)

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments
by: NICOLA SGHERZA, et al.
Published: (2024-02-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
by: A. Visram, et al.
Published: (2023-12-01)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
by: Wassilis S. C. Bruins, et al.
Published: (2024-11-01)

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis
by: Fredrik N. Albach, et al.
Published: (2024-09-01)

Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients
by: Sylvie Hermouet, et al.
Published: (2024-12-01)

De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: the initial Iranian experience
by: Sepideh Paybast, et al.
Published: (2025-10-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Single monoclonal spike characterized as double monoclonal gammopathy in a patient with multiple myeloma: A rare finding
by: Rajni Saijpaul, et al.
Published: (2023-01-01)

Role of Monoclonal Antibodies in the Treatment of Asthma
by: Paul M O’Byrne
Published: (2013-01-01)

MONOCLONAL ANTIBODIES
by: Zekeriya Aksöz
Published: (2024-12-01)

Application of Monoclonal Anti-Mycolate Antibodies in Serological Diagnosis of Tuberculosis
by: Alma Truyts, et al.
Published: (2024-11-01)

A patient with positive anti‐IFN‐γ autoantibody and monoclonal gammaglobulinemia masquerading as multiple myeloma: Case report and literature review
by: Ran An, et al.
Published: (2024-09-01)

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
by: Dirk Schadendorf, et al.
Published: (2024-03-01)

Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
by: Hakan Keski, et al.
Published: (2024-12-01)

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
by: Hovav Azuly, et al.
Published: (2024-12-01)

Rituximab (monoclonal anti-CD20 antibody) induced posterior reversible encephalopathy syndrome (PRES): A case report and literature review
by: Praveen K. Sharma, MD, et al.
Published: (2025-03-01)

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
by: Brajesh P. Kaistha, et al.
Published: (2024-12-01)

Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
by: Hannah W Haddad, et al.
Published: (2022-01-01)

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
by: Hannah W. Haddad, et al.
Published: (2022-07-01)

Anti-CD4 monoclonal antibody prevents chronic graft-versus-host disease in mice by inducing immune tolerance of CD8+ T cells and alleviating thymus injury
by: Ziwei Wang, et al.
Published: (2024-12-01)

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
by: Almodovar Diaz AA, et al.
Published: (2024-12-01)

IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA?
by: Ugo Testa, et al.
Published: (2024-04-01)

Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role
by: Giovanni D’Arena, et al.
Published: (2016-01-01)

Monoclonal Gammopathy of Renal Significance with Progression to Multiple Myeloma in a Patient with ASIA-MO Syndrome
by: David Alejandro Vargas Gutiérrez, et al.
Published: (2022-01-01)

Synchronous Diagnosis of Multiple Myeloma, Breast Cancer, and Monoclonal B-Cell Lymphocytosis on Initial Presentation
by: A. Vennepureddy, et al.
Published: (2016-01-01)

Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome
by: Matteo Giaccherini, et al.
Published: (2024-11-01)

High-throughput single-cell analysis reveals Omp38-specific monoclonal antibodies that protect against Acinetobacter baumannii infection
by: Yiwei Zhang, et al.
Published: (2025-12-01)

Development of specific anti-mouse atypical chemokine receptor 4 monoclonal antibodies
by: Miu Hirose, et al.
Published: (2024-12-01)

Packaging of humanized anti-HER2 monoclonal antibody into small extracellular vesicles
by: Junxin Mai, et al.
Published: (2025-06-01)

Anti-GluK2 antibody-positive autoimmune encephalitis concurrent with multiple myeloma: a case report
by: Zhengping Cheng, et al.
Published: (2025-01-01)

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
by: Jakub Radocha, et al.
Published: (2018-08-01)

IMMUNOHISTOCHEMICALLY EVALUATION OF CD20 EXPRESSION IN PATIENTS WITH MULTIPLE MYELOMA
by: Irfan Yavasoglu, et al.
Published: (2014-08-01)

Spatiotemporal regulation of alginate sub-structures at multiple scales revealed by monoclonal antibodies
by: Catherine T. Jones, et al.
Published: (2025-06-01)

2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
by: Huiqi Yin, et al.
Published: (2024-11-01)